Back to Search Start Over

Target-directed evolution of novel modulators of the dopamine transporter in Lobelia cardinalis hairy root cultures

Authors :
Zachary D. Kelley
Bert C. Lynn
Dennis T. Rogers
Greg A. Gerhardt
John M. Littleton
Francois Pomerleau
Dustin Brown
Source :
J Biotechnol
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

The dopamine transporter (DAT) is targeted in substance use disorders (SUDs), and "non-classical”" DAT inhibitors with low abuse potential are therapeutic candidates. Lobinaline, from Lobelia cardinalis, is an atypical DAT inhibitor lead. Chemical synthesis of lobinaline is challenging; thus, "target-directed evolution" was used for lead optimization. A target protein is expressed in plant cells, and a mutant cell population is selected under conditions where target protein functional inhibition confers a survival advantage. Surviving mutants are "mined" for the targeted activity. Applied to a mutant L. cardinalis cell population expressing the human DAT, we identified 20 mutants overproducing DAT inhibitors. Microanalysis prioritized novel lobinaline derivatives, and we first investigated the more water-soluble lobinaline N-oxide. It inhibited rat synaptosomal [3H]DA uptake with an IC50 similar to lobinaline. Against repeated DA microinjections into the rat striatum, lobinaline produced transient DA clearance reductions. In contrast, lobinaline N-oxide prolongingly increased DA peak amplitudes, particularly in the ventral striatum. Lobinaline N-oxide also produced complex changes in post-peak DA clearance inconsistent with simple DAT inhibition. This unusual DAT interaction may prove therapeutically useful for treating SUDs. This study demonstrates the value of target-directed evolution of plant cells for optimizing lead compounds difficult to synthesize chemically.

Details

ISSN :
01681656
Volume :
342
Database :
OpenAIRE
Journal :
Journal of Biotechnology
Accession number :
edsair.doi.dedup.....2348ecb668ae05e6021aa57bf177b778
Full Text :
https://doi.org/10.1016/j.jbiotec.2021.10.001